Zylox-Tonbridge Sets Detailed Governance Rules for Audit Committee

An announcement from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) is now available.

Zylox-Tonbridge Medical Technology Co., Ltd. has formalised detailed terms of reference for its audit committee, specifying that it must comprise at least three non-executive directors, with a majority being independent and at least one possessing professional accounting or financial management expertise. The committee must be chaired by an independent non-executive director, whose role includes convening and presiding over meetings, while members serve terms aligned with the board and lose membership automatically if they cease to qualify as directors or independent directors.

The rules set out procedures for meetings, requiring at least two regular meetings annually, clear notice periods, quorum thresholds of at least two-thirds of members, and allowing participation through electronic means such as telephone or videoconferencing. Voting arrangements, handling of conflicts of interest through recusal of connected members, and mechanisms for written resolutions are designed to strengthen oversight, enhance transparency, and align the company’s audit governance with Hong Kong Listing Rules, supporting investor confidence and regulatory compliance.

The most recent analyst rating on (HK:2190) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.

More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H

Zylox-Tonbridge Medical Technology Co., Ltd. operates in the medical technology sector, focusing on healthcare devices and solutions. The company is listed on the Hong Kong Stock Exchange and is subject to its corporate governance and listing requirements, including maintaining an effective audit committee structure.

Average Trading Volume: 700,433

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.31B

See more data about 2190 stock on TipRanks’ Stock Analysis page.